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Abstract 
OBJECTIVE: Metabolism of aspirin (acetylsalicylic acid), commonly used in older people for 
the prevention of cardiovascular disease, is important to the effectiveness of this drug. 
Whereas part of aspirin hydrolysis occurs in blood, there is a paucity of information in regards 
to circulating aspirin esterase activity in various physiological and pathological conditions. High 
aspirin esterase activity, corresponding to faster aspirin hydrolysis (thus aspirin 
non-responsiveness), may occur in cardiovascular disease-prone states. The objective of this 
study was to investigate the effects of cardio-metabolic variables such as cholesterol on serum 
aspirin esterase activity in older people who participated in an intervention study on physical 
activity. 
METHODS: A total of 18 non-medicated subjects (7 men/11 women, mean age 67.8 years, 
body mass index = 23.4 ± 3.3 kg/m
2), who completed a 3-month interventional program for a 
mild-to-moderate increase in physical activity, were analyzed. The body mass index, plasma 
glucose, serum total cholesterol and aspirin esterase activity were measured in the pre- and 
post-interventional phases of the study. 
RESULTS: During the interventional period, the changes in aspirin esterase activity cor-
related significantly and positively with those of total cholesterol concentrations (r = 0.542, P 
= 0.020; β = 0.609, P = 0.035 in a multiple linear regression analysis after adjusting for all the 
measured variables). 
CONCLUSION: The results suggest that cholesterol metabolism alterations may be as-
sociated with aspirin metabolism in older people. 
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INTRODUCTION 
Aspirin (acetylsalicylic acid) is one of the most 
frequently used drugs, exploiting its an-
ti-inflammatory and anti-platelet actions for the pre-
vention of cardiovascular disease (1). Especially, for 
this purpose, older people are commonly medicated 
with this agent (2). The so-called ‘aspirin resistance (or 
aspirin non-responsiveness) syndrome’ is characte-
rized by an incomplete inhibition of platelet function 
by aspirin (2, 3). It may account for the high variability 
in effective anti-coagulant doses of aspirin in the 
population (2, 3). Increased hydrolysis of circulating 




elimination of the drug from the circulation by trans-
forming it into salicylate and acetate, is thought to 
participate as a causal factor in the aspirin resistance 
(4, 5). Although the hepatocyte accounts for most of 
aspirin catabolism, after the first pass, more than 50 % 
of the aspirin still gets to the systemic circulation 
where two distinct aspirin hydrolysis pathways act: a 
spontaneous pH-dependent hydrolysis and an en-
zymatic hydrolysis by plasma/serum and erythrocyte 
esterases (6). The circulating aspirin esterase activities 
are mainly due to butyrylcholinesterase (BChE, 
pseudocholinesterase) and, in part, to albumin (6). 
Because of higher aspirin esterase activity lead-
ing to faster aspirin hydrolysis, the same dose of as-
pirin in people who metabolize aspirin slowly is 
more effective than in those who metabolize the 
drug quickly (4, 5). There is a wide range of rates of 
aspirin metabolism in the population, and ethnic and 
individual variations exist (7, 8). Even for a given in-
dividual, age-related factors may be also contributory 
to the range of turnover rates (8). However, despite 
the universal use of aspirin, the underpinnings of the 
etiology of aspirin resistance remain unclear as is the 
putative relative role of peripheral (serum) and cen-
tral (hepatic) metabolism (4-6, 8). 
Recently, a cross-sectional study has reported 
aspirin esterase activity to be increased in type 2 di-
abetics and has shown the association to be mod-
ulated by circulating lipid metabolism (6). In addition, 
aspirin resistance has been previously reported in 
patients with diabetes and cardiovascular disease (4, 
5). However, research on variations of aspirin esterase 
activity in pathological and physiological states, in-
cluding the influences of therapeutic lifestyle modifi-
cations, is very scarce. We set out this study to explore 
preliminarily the effects of cardio-metabolic variables 
such as circulating cholesterol on serum aspirin este-
rase activity among older people who participated in 
an intervention study on physical activity. 
SUBJECTS AND METHODS 
A total of 18 community-dwelling Japanese older 
volunteers (7 men/11women; mean age = 67.8 ± 7.7 
years [range = 56-81 years]), who were not current 
smokers, not on any medication and had not been 
diagnosed to have cardiovascular, renal, kidney, 
thyroid and nutritional diseases, were recruited into a 
3-month interventional program for health promo-
tion. The program, which focused on the health bene-
fits of a mild-to-moderate increase in physical activity, 
included monthly explanatory and motivational 
classes to increase physical activity such as walking 
and to instruct on the appropriate methods. The Jichi 
Medical University ethics committee approved the 
present study and each subject gave informed con-
sent. 
The body mass index (BMI) was calculated as the 
weight divided by the square of the height measured 
in light indoor clothing without shoes. Serum total 
cholesterol and plasma glucose were enzymatically 
determined. Serum aspirin esterase activity was 
measured kinetically by a modification (optimized in 
our laboratory) of the procedure described initially by 
Sorensen (9). The reagent buffer contained Tris-HCl 
(0.6 mol/L) and CaCl2 (0.4 mol/L) in pH 7.6-7.7. Sub-
strate was 555 mmol/L of acetylsalicylic acid (1g in 10 
mL 100 % ethanol was used as the mother solution). 
Briefly, 15 µL of serum sample was pipetted per well 
(in duplicate) into a 96 well UV Flat bottom Plate 
(Thermo 8404). Substrate was extemporaneously di-
luted 1 in 50 into reagent buffer, and then 200 μL of 
this final substrate solution was added per well with a 
multi-channel pipette. The runs were blanked against 
reagent (to control for spontaneous hydrolysis of 
acetylsalicylic acid). Plates were placed in a tempera-
ture-controlled plate reader SpectraMax UV from 
Molecular Devices, and samples were kinetically read 
at 300 nm, 37°C for 15 min, every 57 sec. Data were 
expressed in nmol of acetylsalicylic acid hydrolyzed 
per minute and per milliliter (nmol/mL/min). The 
intra-assay CV (coefficient of variation) is 4% and the 
inter-assay 5%, respectively. 
Data are shown as the mean ± standard devia-
tion or the median [interquartile range]. Wilcoxon test 
was used to compare the pre- and post-interventional 
values of respective measured variables. The level 
changes were calculated by subtracting the 
pre-interventional values from the post-intervention 
values. A single linear regression analysis (Pearson’s 
rank correlation test) and a multiple linear regression 
analysis adjusted for confounders were used to eva-
luate the correlations between the variables. The 
log-transformed values of aspirin esterase were used 
in these correlation analyses because of the skewed 
distribution. A value of P < 0.05 was considered to be 
significant. 
RESULTS 
The intervention on physical activity reduced 
weakly but significantly the BMI levels (23.4 ± 3.3 
kg/m2 at baseline to 23.1 ± 3.0 in post-intervention, P 
= 0.037). The averaged levels of other measured va-
riables between pre- and post-intervention were un-
changed at statistical significant levels: 5.7 ± 1.1 to 5.8 
± 1.1 mmol/L in total cholesterol, 5.6 ± 0.8 to 5.5 ± 1.1 
mmol/L in glucose, 41.4 [36.0-50.0] to 39.8 [34.6-48.1] 




(pre-intervention), aspirin esterase activity levels 
were correlated significantly and inversely to age (r = 
-0.569, P = 0.014). After adjustment for sex, aspirin 
esterase had a significant positive correlation with age 
(r = -0.548, P = 0.020), but the significance of this cor-
relation was lost after adjusting for sex and BMI (r = 
-0.406, P = 0.113). The results were not affected by 
adjustment for total cholesterol and glucose levels. 
During the intervention period, the changes in 
aspirin esterase activity levels were correlated signif-
icantly and positively with those of total cholesterol 
concentrations (Table 1). Moreover, both variables 
showed a significantly and independently positive 
correlation after the adjustments for age (r = 0.534, P = 
0.021), age and sex (r = 0.475, P = 0.035) as well as age, 
sex and the changes in BMI (r = 0.618, P = 0.018). The 
results on the significant, independent and positive 
correlation between total cholesterol and aspirin es-
terase were not affected by adjustment for all the 
measured variables (Table 1). 
Table 1: The correlation between the change in the levels 
(∆ values) of aspirin esterase and the other variables during 
an intervention study period. 
Variables r  (P value)  β (P value) 
For Δ aspirin esterase (nmol/mL/min) 
 A ge (years) -0.276  (0.268) -0.389  (0.100) 
 Sex  (men)   0.352  (0.152)   0.306  (0.173) 
  Δ Body mass index (kg/m2) -0.154  (0.542)   0.295  (0.269) 
  Δ Total cholesterol (mmol/L)   0.542  (0.020)*   0.609  (0.035)* 
  Δ Glucose (mmol/L)   0.249  (0.320)   0.022  (0.922) 
r: correlation coefficient of single linear regression analysis, β: cor-
relation coefficient of multiple linear regression analysis adjusted 
for all the listed variables. Age in the pre-intervention was used as 
age-variable. The level changes (Δ values) were calculated by sub-
tracting the pre-interventional values from the post-interventional 
values. Aspirin esterase is tested after a log-transformation. Signi-
ficance level: * P < 0.05. 
DISCUSSION 
The present study’s main finding is that the 
changes in serum total cholesterol concentrations are 
clearly associated with those of aspirin esterase activ-
ity during a period of physical activity modification in 
an older population. This finding suggests cholesterol 
metabolism alterations may be important in media-
tion of aspirin metabolism among older people. A 
recent report has shown that greater aspirin hydroly-
sis can be associated with decreased cholesterol levels 
of high-density lipoprotein in type 2 diabetics (6). 
Although our present results are not strictly compa-
rable to those of this previous report since that evi-
dence was obtained in diabetics, both studies poten-
tially seem to bring our attention to the notion that 
aspirin hydrolysis rates may be linked to cholesterol 
metabolism (6). Whereas the molecular mechanisms 
underlying the modulation of circulating aspirin es-
terase activity remain to be elucidated, our data 
showing its significant correlations with the changes 
in cholesterol concentrations may open new avenues 
for exploration of aspirin metabolism. Our present 
results of improvement of aspirin effect with de-
creased total cholesterol may partly account for 
non-effectiveness of aspirin in cardiovascular disease 
among patients with concurrent increases of total 
cholesterol levels (4, 5); thus, emphasizing the clinical 
importance of control of total cholesterol with a 
mild-to-moderate increase of physical activity among 
such patients. 
While age-related reductions in the activities of 
several enzymes are known (2), data regarding the 
correlation of age to aspirin esterase are inconsistent 
(2, 10-12). Some studies reported a decrease of aspirin 
esterase in unhealthy, frail older subjects (10-12). Our 
present results at baseline only showed an inverse 
correlation of age to aspirin esterase activity, but the 
present study population was not frail, and BMI was 
also a confounder of this correlation. BMI is a surro-
gate clinical marker for various common clinical syn-
dromes; thus, more research is needed to ascertain its 
role on the effects of aging on aspirin metabolism. 
This study had the limitation of a small sample 
size and a short-term interventional period. In addi-
tion, we did not measure circulating albumin and 
BChE. Nevertheless, albumin has a very small con-
tribution to the whole circulating aspirin esterase ac-
tivity as compared to that of BChE (8), and our study 
population did not include subjects with malnutrition 
nor there were any with nutritional modifications 
during the interventional period. More studies with 
larger sample sizes and longer follow-up as well as 
including BChE measurement and nutritional as-
sessment will be considered in the future. 
In summary, we found a significant and positive 
association of changes in circulating total cholesterol 
with those of serum aspirin esterase activity in an 
older population that participated in a physical activ-
ity modification program. Although aspirin metabol-
ism is probably multi-factorial, the association with 
cholesterol metabolism has merits for further inves-
tigations. 
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